Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Hemophilia A: full-pipeline trial registry
15 of 43 indexed Hemophilia A trials are currently recruiting.
Corpus placement: #339 of 28,707 conditions by registered trial count.
43 US clinical trials · 15 currently recruiting · #339 of 28,707 conditions by registered trial count
Hemophilia A: 43 US clinical trials tracked, 15 recruiting.
Hemophilia A is the subject of 43 registered US clinical trials on ClinicalTrials.gov, 15 of them currently open to new participants. 18 are in Phase 3-4 (later-stage) and 12 in Phase 1-2 (earlier-stage). The most active sponsor is Bayer, running 8 of these trials.
Enrollment posture brief
Registry condition hemophilia-a
OPEN 15 | RECR 35% | LATE 18 | EARLY 12 | RANK #339 | SPON 8
Volume-matched condition peers
Nearest open-share peer: Obsessive - Compulsive Disorder (35% recruiting · 86 trials)
Hemophilia A lists 15 open slots (35% of 43 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Hemophilia A on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Hemophilia A is recruiting below its size-band peers.
15 of 43 indexed trials (34.9%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Hemophilia A research.
Bayer accounts for 8 of 43 trials (18.6%). 24 distinct sponsors appear on at least one study for this condition label.
-
Most Hemophilia A trials plan to enrol fewer than 100 people.
Median target enrolment is 60 among the 43 trials that report a genuine target (sentinel values excluded). 30 of those (69.8%) plan for fewer than 100 participants.
-
Hemophilia A research is mostly interventional.
31 interventional and 12 observational studies make up this index (72.1% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
43 total, page 1 of 1
Hemophilia A Research Program
University of Washington
NCT07414511
Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors
Pfizer
NCT05145127
Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B Respectively
Pfizer
NCT05568719
Treatment of Hemophilia A Patients With FVIII Inhibitors
Emory University
NCT04023019
A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B
Pfizer
NCT05611801
Prevention of Bleeding in Patients With Moderate and Severe Hemophilia A Playing Sports: A Comparison Between Factor VIII and Emicizumab Prophylaxis
Wayne State University
NCT05022459
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of NXT007 in Persons With Severe or Moderate Hemophilia A
Hoffmann-La Roche
NCT05987449
Effects of Emicizumab vs. Factor VIII Prophylaxis on Joint and Bone Health in Severe Hemophilia A
Washington Institute for Coagulation
NCT04131036
A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SR604 in Two Participants Groups (Part A: Healthy Participants, and Part B: Participants With Hemophilia A or Hemophilia B or Factor VII Deficiency)
Equilibra Bioscience
NCT06349473
Nuwiq Dosing and Outcomes In the ManagEment of Women/Girls With Haemophilia A Needing FVIII Treatment for Surgery
Octapharma
NCT05936580
POCUS: Hemostatic Potential and Joint Health in Patients With Severe Hemophilia A on Novel Replacement Therapies
University of Texas Southwestern Medical Center
NCT04690322
A Study to Test a Medicine (Fitusiran) for Preventing Bleeds in People With Severe Hemophilia Who Previously Received Preventive Treatment With Emicizumab
Sanofi
NCT06145373
ASC618 Gene Therapy in Hemophilia A Patients
ASC Therapeutics
NCT04676048
A Gene Therapy Study of SPK-8011QQ in Adults With Severe or Moderately Severe Hemophilia A
Hoffmann-La Roche
NCT07226206
SAFE Study: Safety of aPCC Following Emicizumab Prophylaxis
Emory University
NCT04563520
Evaluating Effectiveness and Long Term Safety of Damoctocog Alfa Pegol in Patients, Who Have Been Diagnosed With Hemophilia A
Bayer
NCT03932201
Long-term Safety and Efficacy of Efanesoctocog Alfa (BIVV001) in Previously Treated Patients With Hemophilia A
Bioverativ, a Sanofi company
NCT04644575
A Long-term Study of ADYNOVI/ADYNOVATE in Participants With Haemophilia A
Baxalta now part of Shire
NCT04158934
A Study to Evaluate Impact of Efanesoctocog Alfa on Long-term Joint Health in Participants With Hemophilia A
Sanofi
NCT05911763
Study to Evaluate the Efficacy and Safety of PF-07055480 / Giroctocogene Fitelparvovec Gene Therapy in Moderately Severe to Severe Hemophilia A Adults
Pfizer
NCT04370054
Long-Term Safety and Efficacy of Spark-Sponsored Gene Therapies in Males With Hemophilia A
Spark Therapeutics
NCT03432520
Gene Therapy for Haemophilia A.
University College, London
NCT03001830
Study to Test the Safety and How Well Patients With Severe Hemophilia A Respond to Treatment With BAY 2599023 (DTX 201), a Drug Therapy That Delivers a Healthy Version of the Defective Factor VIII Gene Into the Nucleus of Liver Cells Using an Altered, Non-infectious Virus (AAV) as a "Shuttle"
Bayer
NCT03588299
Gene Therapy Trial for Platelet Derived Factor VIII Production in Hemophilia A
Medical College of Wisconsin
NCT03818763
Females With Severe or Moderate Hemophilia A or B: an International Multi-center Study
Weill Medical College of Cornell University
NCT00936312
An Open-label Safety, Efficacy and Pharmacokinetic Study of a Recombinant FVIII Compared to Recombinant Human Antihemophilic FVIII in Patients With Severe Hemophilia A
CSL Behring
NCT01486927
A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients Without Inhibitors
Genzyme, a Sanofi Company
NCT03417245
ADVATE Post Authorization Safety Surveillance
Baxalta now part of Shire
NCT00214734
A Study of Emicizumab Administered Subcutaneously (SC) in Pediatric Participants With Hemophilia A and Factor VIII (FVIII) Inhibitors
Hoffmann-La Roche
NCT02795767
Phase 3/4 Study of a Recombinant Protein-Free Factor VIII (rAHF-PFM): Comparison of Continuous Infusion Versus Intermittent Bolus Infusion in Hemophilia A Subjects Undergoing Major Orthopedic Surgery
Baxalta now part of Shire
NCT00357656
Trial to Evaluate the Effect of Secondary Prophylaxis With rFVIII Therapy in Severe Hemophilia A Adult and/or Adolescent Subjects Compared to That of Episodic Treatment
Bayer
NCT00623480
A Trial to Compare Prophylaxis Therapy to On-demand Therapy With a New Full Length Recombinant FVIII in Patients With Severe Hemophilia A
Bayer
NCT01233258
Safety, Efficacy and PK of BIVV001 in Pediatric Patients With Hemophilia A
Bioverativ, a Sanofi company
NCT04759131
Case and Use Scenario Study to Gain Knowledge on the User Needs for a Medical Device for Hemophilia a Monitoring
Enzyre B.V.
NCT06369740
Study Evaluating B-Domain Deleted Recombinant Factor VIII (BDDrFVIII, ReFacto AF) in Patients With Hemophilia A Undergoing Elective Major Surgery
Wyeth is now a wholly owned subsidiary of Pfizer
NCT00243659
Pharmacokinetics and Safety of a Single Intravenous Infusion of BAY 79-4980
Bayer
NCT00629837
Prophylaxis Regimen for Hemophilia A Patients
Bayer
NCT05036278
Correlation Between Vitamin D Status and Bone Mineral Density in Patients With Hemophilia
Virginia Commonwealth University
NCT01090206
Study of rFVIIIFc for Immune Tolerance Induction (ITI) in Haemophilia A Patients With Inhibitors Who Have Failed Previous ITI Therapies
Swedish Orphan Biovitrum
NCT03103542
Trial to Evaluate the Pharmacokinetics and Safety Profile of BAY94-9027 Following Single and Multiple Dose Administration
Bayer
NCT01184820
Study to Learn More About the Physical Activity Level of Patients Suffering From Hemophilia A Treated With Damoctocog Alfa Pegol (LIFE ACTIVE Study)
Bayer
NCT04091386
A Study of BAX 888 in Male Adults With Severe Hemophilia A
Baxalta now part of Shire
NCT03370172
Characterization of Laboratory Response to DDAVP in Adult Hemophilia A Carriers
Emory University
NCT02506023
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 11 |
| Phase 2 | 1 |
| Phase 3 | 12 |
| Phase 4 | 6 |
Top Sponsors
Named interventions
Most-linked intervention names on Hemophilia A records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Hemophilia A trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Hemophilia A page
43 registered trials, 15 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 15 Hemophilia A trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Bayer sponsors the most Hemophilia A trials on record, review their full trial history before evaluating a specific study. See Bayer's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Hemophilia A condition card totals 43 registered trials; most-linked intervention Emicizumab; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.